Slideshow

Endo News Roundup: T1 and T2 Diabetes Management

Author(s):

Three studies show the potential of an artificial pancreas & a less invasive glucose testing device and a 2-drug combo to improve glycemic measures.

A hybrid closed-loop insulin delivery system, or so-called “artificial pancreas,” appears to be safe and effective in patients with T1DM. A novel flash glucose testing device can reduce the time adults with well-controlled T1DM spend in hypoglycemia. A combination of exenatide and dapagliflozin can improve glycemic measures and cardiovascular risk factors better than either drug alone in patients with T2DM inadequately controlled on metformin monotherapy.

Related Videos
Viet Le, DMSc, PA-C | Credit: APAC
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
Diabetes Dialogue: Latest Updates on Semaglutide Shortage, Data | Image Credit: HCPLive
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
HCPLive CKD and CVD NewsNetwork Thumbnail
Richard Pratley, MD | Credit: Advent Health Diabetes Institute
Rahul Aggarwal, MD | Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.